Abiopharma

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) Reports the reporting period Financial Results PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 19884
• Net Income: $31,534
• EPS: Not disclosed
• Cash and equivalents: $48
  • Selected by Basecamp Research to power its Trillion Gene Atlas, which is expected to result in approximately 100,000 samples being deeply sequenced from over 31 countries
  • Announced a collaboration with DNAstack to power the first global federated HiFi whole genome dataset
  • Nx beta program to more customers domestically and internationally after receiving positive feedback from initial users
    • anticipated increases in costs or expenses; high costs of computer memory components; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; potential product performance and quality issues and potential delays in development timelines; the possible loss of key employees, customers, or suppliers; customers and prospective customers curtailing or suspending activities using PacBio's products; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; risks associated with international operations; and other risks associated with general macroeconomic conditions and global economic or political instability, including war and other international conflicts, such as the conflicts in the Middle East. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available. The unaudited condensed consolidated financial statements that follow should be read in conjunction with the notes set forth in PacBio's Quarterly Report on Form 10-Q when filed with the Securities and Exchange Commission. ContactsInvestors:ir@pacb.comMedia:pr@pacb.comPacific Biosciences of California, Inc.Unaudited Condensed Consolidated Statements of OperationsThree Months Ended(in thousands, except per share amounts)March 31,2026